Preventive effects of phytoestrogens against postmenopausal osteoporosis as compared to the available therapeutic choices: An overview

Journal of Natural Science, Biology and Medicine

Volumn 2, Issue 2, 2011, Pages 154-163

  Al Anazi, Abdullah Foraih ^a   Qureshi, Viquar Fatima ^b   Javaid, Khalida ^b   Qureshi, Shoeb ^c  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^b KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^c PRINCE SATTAM BIN ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Menopause; Osteoporosis; Phytoestrogens

Indexed keywords

EID: 84867143621     PISSN: 09769668     EISSN: 22297707     Source Type: Journal    
DOI: 10.4103/0976-9668.92322     Document Type: Review

References (86)

1. Wark JD. Osteoporotic fractures: Background and prevention strategies. Maturitas 1996;2:193-207.
2. Dempster DW, Lindsay R. Pathogenesis of osteoporosis. Lancet 1996;341:797-801.
3. Fitzpatrick LA. Phytoestrogens-mechanism of action and effect on bone markers and bone mineral density. Endocrinol Metab Clin North Am 2003;32:233-52, VIII
4. Cook A, Pennington G. Phytoestrogen and multiple vitamin/mineral effects on bone mineral density in early postmenopausal women: A pilot study. J Womens Health Gend Based Med 2002;11:53-60.
5. Khosla S. Update on estrogens and the skeleton. J Clin Endocrinol Metab 2010;95:3569-77.
6. Rotem C, Kaplan B. Phyto-Female Complex for the relief of hot flushes, night sweats and quality of sleep: Randomized, controlled, double-blind pilot study. Gynecol Endocrinol 2007;23:117-22.
7. Hirata JD, Swiersz LM, Zell B, Small R, Ettinger B. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertil Steril 1997;68:981-6.
8. Tempfer CB, Froese G, Heinze G, Bentz EK, Hefler LA, Huber JC. Side effects of phytoestrogens: A meta-analysis of randomized trials. Am J Med 2009;122:939-46.e9.
9. Aubertin-Leheudre M, Lord C, Khalil A, Dionne IJ. Effect of 6 months of exercise and isoflavone supplementation on clinical cardiovascular risk factors in obese postmenopausal women: A randomized, double-blind study. Menopause 2007;14:624-9.
10. Cooper C. Epidemiology of osteoporosis. Osteoporos Int 1999;9:S2-8.
11. Shilbayeh S. Prevalence of osteoporosis and its reproductive risk factors among Jordanian women: A cross-sectional study. Osteoporos Int 2003;14:929-40.
12. Navarro Rodríguez MC, Saavedra Santana P, de Pablos Velasco P, Sablón González N, de Miguel Ruiz E, Castro Medina R, et al. Lifestyle, socioeconomic status and morbidity in postmenopausal women with grade II and III obesity. Endocrinol Nutr 2009;56: 227-32.
13. MerckMedicus Modules: Osteoporosis - Epidemiology" Available from: (http://web.archive.org/web/200.712.28030929/http://www. merckmedicus.com/pp/us/ hcp/diseasemodules/osteoporosis/ epidemiology.jsp). Merck and Co., Inc. Archived from the original (http://www.merckmedicus.com/pp/us/hcp/diseasemodules/ osteoporosis/epidemiology.jsp) [Last accessed on 2007 Dec 28].
14. Cauley JA, Hochberg MC, Lui LY. "Long-term Risk of Incident Vertebral Fractures". JAMA 2007;298:2761-7.
15. Fogarty P, O'Beirne B, Casey C. Epidemiology of the most frequent diseases in the European a-symptomatic post-menopausal women. Is there any difference between Ireland and the rest of Europe? Maturitas 2005;52 Suppl 1:S3-6.
16. Murrillo-Uribe A, Delezé-Hinojosa M, Aguirre E, Villa A, Calva J, Cons F, et al. Osteoporosis in Mexican postmenopausal women. Magnitude of the problem. Multicenter study. Ginecol Obstet Mex 1999;67:227-33.
17. Raspe A, Matthis C, von Domarus U, Scheidt-Nave C, Abendroth K, Reisinger W, et al. Current musculoskeletal symptoms in peri and postmenopausal women: Results of a multicenter population epidemiological study. The EVOS Study Group. Soz Praventivmed 1994;39:379-86.
18. Gaja A, Zmrzlík P, Gajová B. Contribution to the social importance and the epidemiology of osteoporosis. Acta Univ Palacki Olomuc Fac Med 1993;135:13-5.
19. Hamdi Kara I, Aydin S, Gemalmaz A, Aktürk Z, Yaman H, Bozdemir N, et al. Habitual tea drinking and bone mineral density in postmenopausal Turkish women: investigation of prevalence of postmenopausal osteoporosis in Turkey (IPPOT Study). Int J Vitam Nutr Res 2007;77:389-97.
20. Gur A, Sarac AJ, Nas K, Cevik R. The relationship between educational level and bone mineral density in postmenopausal women. BMC Fam Pract 2004;5:18.
21. Gulbahar S, Sahin E, Baydar M, Bircan C, Kizil R, Manisali M, et al. Hypermobility syndrome increases the risk for low bone mass. Clin Rheumatol 2006;25:511-4.
22. Maalouf G, Salem S, Sandid M, Attallah P, Eid J, Saliba N, et al. Bone mineral density of the Lebanese reference population. Osteoporos Int 2000;11:756-64.
23. Nitzan-Kaluski D, Chinich A, Ifrah A, Merom D, Green MS. Correlates of osteoporosis among Jewish and Arab women aged 45-74 in Israel: National women's health interview survey. J Gend Specif Med 2003;6:17-23.
24. Werner P, Olchovsky D, Vered I. Osteoporosis health-related behavior among healthy peri-menopausal and post-menopausal Israeli Jewish and Arab women. Aging Clin Exp Res 2005;17:100-7.
25. Sidibe EH. Menopause in Africa. Ann Endocrinol (Paris) 2005;66: 105-7.
26. Sallam H, Galal AF, Rashed A. Menopause in Egypt: Past and present perspectives. Climacteric 2006;9:421-9.
27. Noreh J, Sekadde-Kigondu C, Karanja JG, Thagana NG. Median age at menopause in a rural population of western Kenya. East Afr Med J 1997;74:634-8.
28. Addar M, El Desouki M, Babay Z. Correlates of age at menopause and osteoporosis in Saudi women. Clin Exp Obstet Gynecol 2005;32:135-7.
29. Sadat-Ali M, Al-Habdan I, Al-Mulhim AA, El-Hassan AY. Effect of parity on bone mineral density among postmenopausal Saudi Arabian women. Saudi Med J 2005;26:1588-90.
30. Sadat-Ali M, Gullenpet AH, Al-Mulhim F, Al Turki H, Al-Shammary H, Al-Elq A, et al. Osteoporosis-related vertebral fractures in postmenopausal women: Prevalence in a Saudi Arabian sample. East Mediterr Health J 2009;15:1420-5.
31. Sadat-Ali M, Al-Habdan IM, Al-Mulhim FA, El-Hassan AY. Bone mineral density among postmenopausal Saudi women. Saudi Med J 2004;25:1623-5.
32. Keramat A, Patwardhan B, Larijani B, Chopra A, Mithal A, Chakravarty D, et al. The assessment of osteoporosis risk factors in Iranian women compared with Indian women. BMC Musculoskelet Disord 2008;9:28.
33. Shatrugna V, Kulkarni B, Kumar PA, Rani KU, Balakrishna N. Bone status of Indian women from a low-income group and its relationship to the nutritional status. Osteoporos Int 2005;16:1827-35.
34. Chailurkit LO, Piaseu N, Rajatanavin R. Influence of normal ageing on mechanism of bone loss in women and men in Bangkok. J Med Assoc Thai 2002;85:915-21.
35. Limpaphayom KK, Taechakraichana N, Jaisamrarn U, Bunyavejchevin S, Chaikittisilpa S, Poshyachinda M, et al. Prevalence of osteopenia and osteoporosis in Thai women. Menopause 2001;8:65-9.
36. Huang KE. Menopause perspectives and treatment of Asian women. Semin Reprod Med 2010;28:396-403.
37. Khan A. Advances in osteoporosis therapy. 2003 Can Fam Physician 2003;49:441-7.
38. Alden JC. Osteoporosis - A review. Clin Ther 1989;11:3-14.
39. Hoeger KM, Guzick DS. The use of androgens in menopause. Clin Obstet Gynecol 1999;42:883-94.
40. Ebeling PR. "Clinical practice. Osteoporosis in men". N Engl J Med 2008;358:1474-82.
41. Davis S, Sachdeva A, Goeckeritz B, Oliver A. Approved treatments for osteoporosis and what's in the pipeline. Drug Benefit Trends 2010;22:121-4.
42. National Prescribing Service. "Zoledronic Acid for osteoporosis" Medcines Update, 2009. Available from: http://www.nps.org.au/ consumers/publications/medicine-update/issues/Zoledronic-acid. [Last accessed on 2011 Jan 27].
43. Meunier PJ, Roux C, Seeman E. "The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis". N Engl J Med 2004;350:459-68.
44. Report of a joint WHO/FAO/UNU Expert consultation. Protein and amino acid requirements in human nutrition. Available from: (http:// whqlibdoc.who.int/ trs/WHO-TRS-935-eng.pdf). 2007. p. 224-6.
45. Rossouw JE, Anderson GL, Prentice RL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321.
46. Cosman F, Lindsay R. Selective estrogen receptor modulators: Clinical spectrum. Endocr Rev 1999;20:418-34.
47. Verhaar, HJ. Treatment of osteoporosis in the elderly: What is the evidence? Tijdschr Gerontol Geriatr 2008;39:168-75.
48. Bretler DM, Hansen PR, Abildstrom SZ, Jorgensen CH, Sorensen R, Hansen ML, et al. Use and discontinuation of hormone replacement therapy in women with mnyocardial infarction: A nationwide study. Br J Clin Pharmacol 2011;71:105-15.
49. Johannes CB, Crawford SL, Posner JG, McKinlay SM. Longitudinal patterns and correlates of hormone replacement therapy use in middle-aged women. Am J Epidemiol 1994;140:439.
50. Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. a prospective, observational study. Ann Intern Med 2001;135:1-8.
51. Battaglioli T, Martinelli I. Hormone therapy and thromboembolic disease. Curr Opin Hematol 2007;14:488-93.
52. Studd J. Profox - the post HRT nightmare. Climacteric 2011;14:217-9.
53. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010;304:1684-92.
54. This P, De La Rochefordiere A, Clough K, Fourquet A, Magdelenat H. Breast Cancer Group of the Institut Curie. Phytoestrogens after breast cancer. Endocr Relat Cancer 2001;8:129-34.
55. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047-59.
56. McVeigh C. Withdrawal of synthetic hormones during the perimenopause: A case study. J Psychosom Obstet Gynaecol 2000;21:175-8.
57. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY. et al. Effect of para thyroid hormone (1-34) on frasctures and bone mneral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-41.
58. Pickar JH, Mirkin S. Tissue-selective agents: Selective estrogen receptor modulators and the tissue-selective estrogen complex. Menopause Int 2010;16:121-8.
59. Barrett-Connor E, Mosca L, Collins P. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125.
60. Modelska K, Cummings S. Tibolone for postmenopausal women: Systematic review of randomized trials. J Clin Endocrinol Metab 2002;87:16.
61. Smolinski D, Wollner D, Orlowski J, Curcio J, Nevels J, Kim LS. A pilot study to examine a combination botanical for the treatment of menopausal symptoms. J Altern Complement Med 2005;11:483-9.
62. Limer JL, Speirs V. Phyto-oestrogens and breast cancer chemoprevention. Breast Cancer Res 2004;6:119-27.
63. Ha H, Lee YS, Lee JH, Choi H, Kim C. High performance liquid chromatographic analysis of isoflavones in medicinal herbs. Arch Pharm Res 2006;29:96-101.
64. Grippo AA, Capps K, Rougeau B, Gurley BJ. Analysis of flaonoid phytoestrogens in botanical and ephedra-containing dietary supplements. Ann Pharmacother 2007;41:1375-82.
65. Franke AA, Halm BM, Kakazu K, Li X, Custer LJ. Phytoestrogenic isoflavonoids in epidemiologic and clinical research. Drug Test Anal 2009;1:14-21.
66. Foth D, Cline JM, Römer T. Effect of isoflavones on mammary gland and endometrium of postmenopausal macaques (Macaca fascicularis). Zentralbl Gynakol 2000;122:96-102.
67. Atmaca A, Kleerekoper M, Bayraktar M, Kucuk O. Soy isoflavones in the management of postmenopausal osteoporosis. Menopause 2008;15:748-57.
68. Joo SS, Won TJ, Kang HC, Lee DI. Isoflavones extracted from Sophorae fructus upregulate IGF-I and TGF-beta and inhibit osteoclastogenesis in rat bone marrow cells. Arch Pharm Res 2004;27:99-105.
69. Anderson JJ, Garner SC. Phytoestrogens and bone. Baillieres Clin Endocrinol Metab 1998;12:543-57.
70. Hooshmand S, Juma S, Arjmandi BH. Combination of genistin and fructo oligosaccharides prevents bone loss in ovarian hormone deficiency. J Med Food 2010;13:320-5.
71. Zittermann A, Geppert J, Baier S, Zehn N, Gouni-Berthold I, Berthold HK, et al. Short-term effects of high soy supplementation on sex hormones, bone markers, and lipid parameters in young female adults. Eur J Nutr 2004;43:100-8.
72. Ju YH, Doerge DR, Helferich WG. A dietary supplement for female sexual dysfunction, Avlimil, stimulates the growth of estrogendependent breast tumors (MCF-7) implanted in ovariectomized athymic nude mice. Food Chem Toxicol 2008;46:310-20.
73. Oerter Klein K, Janfaza M, Wong JA, Chang RJ. Estrogen bioactivity in fo-ti and other herbs used for their estrogen-like effects as determined by a recombinant cell bioassay. J Clin Endocrinol Metab 2003;88:4077-9.
74. Ganry O. Phytoestrogens and prostate cancer risk. Prev Med 2005;41:1-6.
75. Moutsatsou P. The spectrum of phytoestrogens in nature: Our knowledge is expanding. Hormones (Athens) 2007;6:173-93.
76. Dong TT, Zhao KJ, Gao QT, Ji ZN, Zhu TT, Li J, et al. Chemical and biological assessment of a chinese herbal decoction containing Radix Astragali and Radix Angelicae Sinensis: Determination of drug ratio in having optimized properties. J Agric Food Chem 2006;54:2767-74.
77. Booth NL, Piersen CE, Banuvar S, Geller SE, Shulman LP, Farnsworth NR. Clinical studies of red clover (Trifolium pratense) dietary supplements in menopause: A literature review. Menopause 2006;13:251-64.
78. Whelan AM, Jurgens TM, Bowles SK. Natural health products in the prevention and treatment of osteoporosis: Systematic review of randomized controlled trials. Ann Pharmacother 2006;40:836-49.
79. Das AS, Das D, Mukherjee M, Mukherjee S, Mitra C. Phytoestrogenic effects of black tea extract (Camellia sinensis) in an oophorectomized rat (Rattus norvegicus) model of osteoporosis. Life Sci 2005;77: 3049-57.
80. Reinwald S, Weaver CM. Soy isoflavones and bone health: A doubleedged sword? J Nat Prod 2006;69:450-9.
81. Johnson EB, Muto MG, Yanushpolsky EH, Mutter GL. Phytoestrogen supplementation and endometrial cancer. Obstet Gynecol 2001;98:947-50.
82. McLachlan JA, Simpson E, Martin M. Endocrine disrupters and female reproductive health. Best Pract Res Clin Endocrinol Metab 2006;20:63-75.
83. Obermeyer WR, Musser SM, Betz JM, Casey RE, Pohland AE, Page SW. Chemical studies of phytoestrogens and related compounds in dietary supplements: Flax and chaparral. Proc Soc Exp Biol Med 1995;208:6-12.
84. Albertazzi P, Purdie D. The nature and utility of the phytoestrogens: A review of the evidence. Maturitas 2002;42:173-85.
85. Geller SE, Studee L. Botanical and dietary supplements for menopausal symptoms: What works, what does not. J Womens Health (Larchmt) 2005;14:634-49.
86. Jiang X, Patterson NM, Ling Y, Xie J, Helferich WG, Shapiro DJ. Low concentrations of the soy phytoestrogen genistein induce proteinase inhibitor 9 and block killing of breast cancer cells by immune cells. Endocrinology 2008;149:5366-73.